Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

PURPOSE: Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1-mutated breast cancers. Because sporadic triple-negative breast cancer (TNBC) and BRCA1-associated breast cancer shar...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Silver, Daniel P., Richardson, Andrea L., Eklund, Aron C., Wang, Zhigang C., Szallasi, Zoltan, Li, Qiyuan, Juul, Nicolai, Leong, Chee-Onn, Calogrias, Diana, Buraimoh, Ayodele, Fatima, Aquila, Gelman, Rebecca S., Ryan, Paula D., Tung, Nadine M., De Nicolo, Arcangela, Ganesan, Shridar, Miron, Alexander, Colin, Christian, Sgroi, Dennis C., Ellisen, Leif W., Winer, Eric P., Garber, Judy E.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2010
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834466/
https://ncbi.nlm.nih.gov/pubmed/20100965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.4725
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires